Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains
an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional …

Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of
acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 …

The design of next-generation bNAb-based combination or multispecific therapeutics for the
prevention and/or treatment of HIV-1 infection will need to leverage the complementarity of …

Broadly Neutralizing Antibodies: Magic Bullets against HIV?: Immunity Skip to Main Content
Skip to Main Menu Advertisement Immunity This journal offers authors two options (open …

Recent biological, structural, and technical advances are converging within the HIV-1
vaccine field to harness the power of antibodies for prevention and therapy. Numerous …

Broadly neutralizing antibodies (bnAbs) targeting the human immunodeficiency virus-1 (HIV-
1) have played a crucial role in elucidating and characterizing neutralization-sensitive sites …

Introduction: The currently available anti-HIV-1 drugs can control the infection but do not
eradicate the virus. Their long-term use can lead to side effects and resistance to therapy …

The number of new HIV acquisitions globally has declined, but not rapidly enough to meet
the 2030 targets set by UNAIDS and the United Nations Sustainable Development Goals …

Highlights•Broadly neutralizing antibodies are promising for HIV-1 prevention and
therapy.•Newly identified bNAbs reveal novel epitopes and binding modes.•Effective …

Despite substantial progress in confronting the global HIV-1 epidemic since its inception in
the 1980s, better approaches for both treatment and prevention will be necessary to end the …